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With respect to the other comments, we
respectfully disagree:
(i) Lack of risk-adjusted analyses: we
believe this was not warranted as
there was no imbalance in the baseline
characteristics between randomly
assigned groups. Another reason for
adjusting is to increase the precision
with which the treatment effect is
estimated, but this is only relevant to
normal regression models and not to
the Cox model used in this study.2
(ii) We used a composite outcome
measure including mortality as the
primary endpoint, as the compared
treatments were expected to impact
mortality and major morbidity, result-
ing in an increased power when
compared with mortality alone. As
recommended by the ICH harmonized
tripartite guideline, the outcomes
that contributed to the composite
outcome were associated with the
primary objective of the trial, and
the components of the composite
outcome were defined as secondary
outcomes and reported alongside the
results of the primary analysis in a
table. As no difference was observed
for any endpoint, adjustment for mul-
tiplicity would have not modified the
conclusions of the trial.
(iii) Using a secondary endpoint combining
the primary endpoint and admission
for heart failure has not ‘created a
shadow of uncertainty’ but is a stan-
dard procedure in trials ascertaining
the benefit of interventions in heart
failure. In addition, all admissions
were validated by a critical event
committee.
(iv) Length of the study: although we agree
that, in principle, it would be ideal to
have long-term follow-up, 34 months
duration as in DECOPI, it is expected
to offset any initial risks related to
early harm from the procedure.
(v) Absence of coronary angiography
beyond 6 months: in our study, all the
patients underwent a baseline angio-
gram and a repeat angiogram at 6
months. We believe that it would be
difficult to justify a third coronary
angiogram, especially if the trial is
powered on clinical outcomes.
(vi) We are thankful to Dr Achrafi for
reminding us of the importance of
myocardial perfusion as opposed to
epicardial coronary revascularization
in assessing the outcome of percuta-
neous coronary intervention in the
setting of acute myocardial infarc-
tion,3 but we fail to understand the
point of myocardial contrast echocar-
diography or intracoronary Doppler
flow velocity mapping in a clinical out-
comes trial.
(vii) Finally, Dr Achrafi recommends
substituting left ventricular ejection
fraction with other measures which
he believes are better correlated to
survival, some of which are unfamiliar
to us. However, left ventricular
ejection fraction remains a simple,
clinically meaningful index, highly cor-
related to long-term outcomes in the
post-myocardial infarction setting.
Although we welcome scientific discussion
and open criticism, we must also disagree
with the concept that DECOPI brought
‘more smoke on the horizon’. On the con-
trary, we believe that the ultimate truth in
science is often reached through progressive
reduction in uncertainty brought by cumula-
tive evidence from multiple trials.
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Quinidine plus verapamil vs. quinidine
alone to prevent recurrences of atrial
fibrillation
The excellent PAFAC1 and SOPAT2 trials
demonstrated that quinidine, in combination
with verapamil, is at least equivalent to
sotalol in the prevention of recurrences of
atrial fibrillation (AF). The combination of
verapamil with quinidine in this setting may
be beneficial for several reasons. First, vera-
pamil has the ability of suppressing after
depolarizations underlying the onset of tor-
sades de pointes, which justifies the low
rate of pro-arrhythmic events observed with
quinidine during the follow-up period of
these trials.1–3 Secondly, it has been already
demonstrated that the addition of verapamil
to Class IC or III antiarrhythmic drugs signifi-
cantly reduces recurrences of AF,4 an effect
that may also occur with quinidine, a Class
IA drug. Finally, the concomitant adminis-
tration of verapamil is also desirable to
avoid arrhythmia recurrences with high ven-
tricular rates due to enhanced atrioventricu-
lar conduction promoted by the vagolytic
effect of quinidine. Despite all these benefits,
clinical trials routinely did not use the combi-
nation of quinidine with verapamil. Thus, we
expected that the PAFAC and the SOPAT trials
had explored the clinical effects of this
association throughout. These trials clearly
presented the efficacy and the pro-arrhyth-
mic complications of antiarrhythmic
therapy, but failed in presenting the ventricu-
lar rates during recurrences of AF.
Comparing quinidine alone vs. sotalol
to prevent arrhythmia recurrences after
chemical or electrical cardioversion of AF,
we observed that sotalol tended to be
associated with more tolerated recurrences
when compared with quinidine, which was
related to a decrease in ventricular rates
during recurrences, from a mean of
98+ 18 b.p.m. in the baseline recording
before conversion to 82+ 20 b.p.m. during
treatment (P ¼ 0.02).5 In the quinidine
group, ventricular rates tended to in-
crease during recurrence, from a mean of
102+ 28 b.p.m. in the initial episode to
113+ 44 b.p.m. (P ¼ 0.06). Another ran-
domized trial comparing quinidine alone vs.
sotalol also demonstrated that ventricular
rate after relapsing into AF was higher in
patients treated with quinidine (109 b.p.m.)
when compared with patients treated with
sotalol (78 b.p.m., P, 0.001).6 In this study,
patients treated with sotalol were also less
symptomatic at the time of relapse when
compared with relapsing patients in the
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quinidine group. Differently from the PAFAC
and the SOPAT trials, these previous studies
were limited because they did not use trans-
telephonic electrocardiographic monitoring
to detect asymptomatic or short episodes of
paroxysmal arrhythmia.
In conclusion, the results of the PAFAC and
the SOPAT trials strongly suggest that the
combination of quinidine with verapamil is
superior to quinidine alone in patients with
AF. The theoretical benefits of this combi-
nation when compared with quinidine alone
to reduce recurrence rate of AF, avoid pro-
arrhythmic events, and control ventricular
rates during arrhythmia recurrence should
be investigated in a randomized trial.
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